Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Skye Bioscience, Inc.

Get SEC filing alerts via email and in your feed for Skye Bioscience, Inc.

SKYE

Skye Bioscience, Inc.

About Skye Bioscience, Inc.

Skye Bioscience, Inc. is a biotechnology company developing GPCR-modulating molecules for obesity and metabolic disorders. Its lead candidate, nimacimab, is a monoclonal antibody targeting peripheral CB1 receptors to promote weight loss, energy expenditure, and metabolic health. The company focuses on clinical-stage therapeutics, leveraging proprietary platform technologies, with a competitive edge in safety, specificity, and innovative mechanisms to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Skye Bioscience, Inc.

1
1
Skye Bioscience, Inc. Skye Bioscience Reports $12.5 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
Skye Bioscience, Inc. Skye Bioscience Reports $55.92 Million Net Loss for 2025 and Business Update

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Skye Bioscience, Inc. Skye Bioscience Reports $12.8 Million Net Loss and Increased R&D Expenses in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Skye Bioscience, Inc. Skye Bioscience Reports $17.6 Million Net Loss and Increased Expenses in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Skye Bioscience, Inc. Skye Bioscience Reports Increased Net Loss and Rising R&D Expenses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Skye Bioscience, Inc. Skye Bioscience Reports $26.6 Million Net Loss, Advances Nimacimab in Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Skye Bioscience, Inc. Skye Bioscience Reports Significant Financial Developments, Commences Phase 2 Clinical Trial for Lead Drug Candidate

Via official filing (AI summary) | over 1 year ago | 0 comments